Italian drugmaker
Angelini and Recordati have been discussing the possibility of a deal that would create a larger European generic drugmaker, said the people, who asked not to be identified as the information is private. Private equity suitors’ interest in Recordati has waned, the people said.
Bloomberg News
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.